Charles River Laboratories | CRL - Net Income


Charles River Laboratories reported $-14.84M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Agilent USD 339M 34M Mar/2026
Align Technology USD 112.77M 22.99M Mar/2026
Bio-Rad Laboratories USD 720M 1.06B Dec/2025
Bruker USD 3.5M 22.5M Mar/2026
Cardinal Health USD 399M 68M Mar/2026
Charles River Laboratories USD -14.84M 261.71M Mar/2026
Cigna USD 1.65B 420M Mar/2026
Concord Medical Services Hldg CNY -27.14M 63.85M Jun/2025
CVS Health USD 2.94B 0 Mar/2026
Danaher USD 1.03B 168M Mar/2026
Dentsply International USD -10M 136M Mar/2026
Elevance Health USD 1.76B 1.22B Mar/2026
Humana USD 1.19B 1.98B Mar/2026
Illumina USD 134M 200M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
IQVIA Holdings USD 274M 240M Mar/2026
Laboratory Of America USD 277.8M 113.1M Mar/2026
Lakefront Biotherapeutics EUR 14.49M 767.65M Mar/2026
Lonza CHF 426M 119M Jun/2025
McKesson USD 1.68B 496M Mar/2026
Merck EUR 659M 340M Mar/2026
Mettler Toledo International USD 169.45M 116.31M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Quest Diagnostics USD 251M 6M Mar/2026
Revvity USD 40.72M 57.65M Mar/2026
Thermo Fisher Scientific USD 1.65B 313M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
UnitedHealth USD 6.28B 6.27B Mar/2026
Veradigm USD -59.82M 74.35M Dec/2022
Waters USD -72M 297.21M Mar/2026
West Pharmaceutical Services USD 138.8M 6.7M Mar/2026